Our ground-breaking pharmaceutical technology is focused on treating very late-stage or metastatic cancer (stage 4), as well as cancer that is considered terminal, so that we can potentially give hope and effective treatment options to patients and their families that desperately need it the most. We are initially going to focus on treating brain metastatic cancer, which currently does not have effective chemotherapeutic options, and will then expand to other organs afterwards. Our efforts will also focus on treating other neurological conditions, such as dementia, including Alzheimer's. We are close to starting our first trials with some very promising anti-cancer candidate molecules.